Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder

Shahrokh F. Shariat, Ja Hong Kim, Gustavo E. Ayala, Kimberly Kho, Thomas M. Wheeler, Seth P. Lerner

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

Purpose: We describe cyclooxygenase-2 (COX-2) expression patterns in patients with carcinoma in situ and/or stage T1 transitional cell carcinoma. We determined whether expression is associated with clinical outcome in these patients. Materials and Methods: Immunostaining for COX-2 was performed on paraffin embedded bladder biopsy specimens from 2 independent groups of patients without muscle invasive carcinoma, including 39 with carcinoma in situ and 34 with stage T1 tumors. Immunoreactivity was scored as the percent of carcinoma in situ cells with cytoplasmic staining for COX-2 in the carcinoma in situ group and as the percent of stage T1 cells expressing COX-2 in the stage T1 transitional cell carcinoma group. We evaluated other molecular alterations, including E-cadherin, p21 and p53, because evidence suggests a biological association of COX-2 with alterations in these molecular markers. Results: In the carcinoma in situ group 5 patients (13%) had no immunoreactivity, while 2 (5%), 5 (13%) and 27 (69%) had 10%, 20% and 30% or greater carcinoma in situ cells positive for COX-2, respectively. In the transitional cell carcinoma group 1 (3%), 4 (12%) and 29 (85%) patients had 10%, 20% and 30% or greater positive cells, respectively. COX-2 expression was not associated with any clinical or pathological parameters, or with molecular markers regardless of the cutoff used. It was also not associated with clinical outcomes in the stage T1 transitional cell carcinoma group. In the carcinoma in situ group COX-2 expression was significantly associated with disease recurrence using cutoffs of 0% and greater than 10% positive cells, and with disease progression using a greater than 20% cutoff. However, it was not associated with bladder cancer related survival. Conclusions: COX-2 is expressed in a high percent of patients with carcinoma in situ and stage T1 transitional cell carcinoma, supporting the rationale for chemoprevention studies with selective COX-2. We could not substantiate a role for COX-2 immunohistochemistry for the staging and prognosis of carcinoma in situ and/or stage T1 transitional cell carcinoma.

Original languageEnglish (US)
Pages (from-to)938-942
Number of pages5
JournalJournal of Urology
Volume169
Issue number3
DOIs
StatePublished - Mar 1 2003

Fingerprint

Transitional Cell Carcinoma
Carcinoma in Situ
Cyclooxygenase 2
Urinary Bladder
Chemoprevention
Cadherins
Urinary Bladder Neoplasms
Paraffin
Disease Progression
Immunohistochemistry
Staining and Labeling
Carcinoma
Biopsy
Recurrence

Keywords

  • Bladder
  • Bladder neoplasms
  • Carcinoma in situ
  • Prostaglandins

ASJC Scopus subject areas

  • Urology

Cite this

Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder. / Shariat, Shahrokh F.; Kim, Ja Hong; Ayala, Gustavo E.; Kho, Kimberly; Wheeler, Thomas M.; Lerner, Seth P.

In: Journal of Urology, Vol. 169, No. 3, 01.03.2003, p. 938-942.

Research output: Contribution to journalArticle

Shariat, Shahrokh F. ; Kim, Ja Hong ; Ayala, Gustavo E. ; Kho, Kimberly ; Wheeler, Thomas M. ; Lerner, Seth P. / Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder. In: Journal of Urology. 2003 ; Vol. 169, No. 3. pp. 938-942.
@article{e0eb6fde73e84604b5e0ff5e1e62ac3d,
title = "Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder",
abstract = "Purpose: We describe cyclooxygenase-2 (COX-2) expression patterns in patients with carcinoma in situ and/or stage T1 transitional cell carcinoma. We determined whether expression is associated with clinical outcome in these patients. Materials and Methods: Immunostaining for COX-2 was performed on paraffin embedded bladder biopsy specimens from 2 independent groups of patients without muscle invasive carcinoma, including 39 with carcinoma in situ and 34 with stage T1 tumors. Immunoreactivity was scored as the percent of carcinoma in situ cells with cytoplasmic staining for COX-2 in the carcinoma in situ group and as the percent of stage T1 cells expressing COX-2 in the stage T1 transitional cell carcinoma group. We evaluated other molecular alterations, including E-cadherin, p21 and p53, because evidence suggests a biological association of COX-2 with alterations in these molecular markers. Results: In the carcinoma in situ group 5 patients (13{\%}) had no immunoreactivity, while 2 (5{\%}), 5 (13{\%}) and 27 (69{\%}) had 10{\%}, 20{\%} and 30{\%} or greater carcinoma in situ cells positive for COX-2, respectively. In the transitional cell carcinoma group 1 (3{\%}), 4 (12{\%}) and 29 (85{\%}) patients had 10{\%}, 20{\%} and 30{\%} or greater positive cells, respectively. COX-2 expression was not associated with any clinical or pathological parameters, or with molecular markers regardless of the cutoff used. It was also not associated with clinical outcomes in the stage T1 transitional cell carcinoma group. In the carcinoma in situ group COX-2 expression was significantly associated with disease recurrence using cutoffs of 0{\%} and greater than 10{\%} positive cells, and with disease progression using a greater than 20{\%} cutoff. However, it was not associated with bladder cancer related survival. Conclusions: COX-2 is expressed in a high percent of patients with carcinoma in situ and stage T1 transitional cell carcinoma, supporting the rationale for chemoprevention studies with selective COX-2. We could not substantiate a role for COX-2 immunohistochemistry for the staging and prognosis of carcinoma in situ and/or stage T1 transitional cell carcinoma.",
keywords = "Bladder, Bladder neoplasms, Carcinoma in situ, Prostaglandins",
author = "Shariat, {Shahrokh F.} and Kim, {Ja Hong} and Ayala, {Gustavo E.} and Kimberly Kho and Wheeler, {Thomas M.} and Lerner, {Seth P.}",
year = "2003",
month = "3",
day = "1",
doi = "10.1097/01.ju.0000043638.89552.ed",
language = "English (US)",
volume = "169",
pages = "938--942",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder

AU - Shariat, Shahrokh F.

AU - Kim, Ja Hong

AU - Ayala, Gustavo E.

AU - Kho, Kimberly

AU - Wheeler, Thomas M.

AU - Lerner, Seth P.

PY - 2003/3/1

Y1 - 2003/3/1

N2 - Purpose: We describe cyclooxygenase-2 (COX-2) expression patterns in patients with carcinoma in situ and/or stage T1 transitional cell carcinoma. We determined whether expression is associated with clinical outcome in these patients. Materials and Methods: Immunostaining for COX-2 was performed on paraffin embedded bladder biopsy specimens from 2 independent groups of patients without muscle invasive carcinoma, including 39 with carcinoma in situ and 34 with stage T1 tumors. Immunoreactivity was scored as the percent of carcinoma in situ cells with cytoplasmic staining for COX-2 in the carcinoma in situ group and as the percent of stage T1 cells expressing COX-2 in the stage T1 transitional cell carcinoma group. We evaluated other molecular alterations, including E-cadherin, p21 and p53, because evidence suggests a biological association of COX-2 with alterations in these molecular markers. Results: In the carcinoma in situ group 5 patients (13%) had no immunoreactivity, while 2 (5%), 5 (13%) and 27 (69%) had 10%, 20% and 30% or greater carcinoma in situ cells positive for COX-2, respectively. In the transitional cell carcinoma group 1 (3%), 4 (12%) and 29 (85%) patients had 10%, 20% and 30% or greater positive cells, respectively. COX-2 expression was not associated with any clinical or pathological parameters, or with molecular markers regardless of the cutoff used. It was also not associated with clinical outcomes in the stage T1 transitional cell carcinoma group. In the carcinoma in situ group COX-2 expression was significantly associated with disease recurrence using cutoffs of 0% and greater than 10% positive cells, and with disease progression using a greater than 20% cutoff. However, it was not associated with bladder cancer related survival. Conclusions: COX-2 is expressed in a high percent of patients with carcinoma in situ and stage T1 transitional cell carcinoma, supporting the rationale for chemoprevention studies with selective COX-2. We could not substantiate a role for COX-2 immunohistochemistry for the staging and prognosis of carcinoma in situ and/or stage T1 transitional cell carcinoma.

AB - Purpose: We describe cyclooxygenase-2 (COX-2) expression patterns in patients with carcinoma in situ and/or stage T1 transitional cell carcinoma. We determined whether expression is associated with clinical outcome in these patients. Materials and Methods: Immunostaining for COX-2 was performed on paraffin embedded bladder biopsy specimens from 2 independent groups of patients without muscle invasive carcinoma, including 39 with carcinoma in situ and 34 with stage T1 tumors. Immunoreactivity was scored as the percent of carcinoma in situ cells with cytoplasmic staining for COX-2 in the carcinoma in situ group and as the percent of stage T1 cells expressing COX-2 in the stage T1 transitional cell carcinoma group. We evaluated other molecular alterations, including E-cadherin, p21 and p53, because evidence suggests a biological association of COX-2 with alterations in these molecular markers. Results: In the carcinoma in situ group 5 patients (13%) had no immunoreactivity, while 2 (5%), 5 (13%) and 27 (69%) had 10%, 20% and 30% or greater carcinoma in situ cells positive for COX-2, respectively. In the transitional cell carcinoma group 1 (3%), 4 (12%) and 29 (85%) patients had 10%, 20% and 30% or greater positive cells, respectively. COX-2 expression was not associated with any clinical or pathological parameters, or with molecular markers regardless of the cutoff used. It was also not associated with clinical outcomes in the stage T1 transitional cell carcinoma group. In the carcinoma in situ group COX-2 expression was significantly associated with disease recurrence using cutoffs of 0% and greater than 10% positive cells, and with disease progression using a greater than 20% cutoff. However, it was not associated with bladder cancer related survival. Conclusions: COX-2 is expressed in a high percent of patients with carcinoma in situ and stage T1 transitional cell carcinoma, supporting the rationale for chemoprevention studies with selective COX-2. We could not substantiate a role for COX-2 immunohistochemistry for the staging and prognosis of carcinoma in situ and/or stage T1 transitional cell carcinoma.

KW - Bladder

KW - Bladder neoplasms

KW - Carcinoma in situ

KW - Prostaglandins

UR - http://www.scopus.com/inward/record.url?scp=0037366062&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037366062&partnerID=8YFLogxK

U2 - 10.1097/01.ju.0000043638.89552.ed

DO - 10.1097/01.ju.0000043638.89552.ed

M3 - Article

C2 - 12576817

AN - SCOPUS:0037366062

VL - 169

SP - 938

EP - 942

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 3

ER -